Glatiramer Acetate Injection, Solution
Product Images NDC 47335-990

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 47335-990). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Glatirtamer Actetate Injection (Glatiramer Acetate 20 mg Per mL 1)

A Kaplan-Meier survival curve comparing Glatiramer acetate injection 20 mg/mL and placebo over approximately 1000 days. The graph shows the percentage of events on the vertical axis and time in days on the horizontal axis, indicating a lower event rate for Glatiramer acetate versus placebo, with statistical annotations including p-value and hazard ratio.*

FDA Label Image

Figure G (Glatiramer Acetate 20 mg Per mL 10)

An instructional illustration shows a person administering a subcutaneous injection into the abdomen using a prefilled syringe. One hand holds the syringe vertically while the other stretches the skin below the injection site. The image demonstrates correct injection technique.*

FDA Label Image

Figure H (Glatiramer Acetate 20 mg Per mL 11)

An instructional line drawing illustrating a person administering a subcutaneous injection with a syringe into the abdomen area using one hand while the other hand stabilizes the skin.*

FDA Label Image

Figure I (Glatiramer Acetate 20 mg Per mL 12)

Illustration showing a hand holding a syringe vertically while the other hand steadies a vial. The syringe is being used to withdraw solution from the vial, demonstrating preparation of an injection.*

FDA Label Image

Figure J (Glatiramer Acetate 20 mg Per mL 13)

An instructional illustration showing a hand injecting a solution subcutaneously with a syringe. The image focuses on proper injection technique into the skin, relevant to subcutaneous administration of Glatiramer Acetate injection.*

FDA Label Image

Figure K (Glatiramer Acetate 20 mg Per mL 14)

An illustration showing a person applying a topical product to the skin of their thigh using their fingers. The image demonstrates the method of spreading or rubbing the product onto the skin.*

FDA Label Image

Figure L (Glatiramer Acetate 20 mg Per mL 15)

An illustration of a closed biohazard sharps container, typically used for safe disposal of needles and other sharp medical waste. The container is rectangular with a hinged lid and displays a biohazard symbol on the front.*

FDA Label Image

Logo Sun Pharma (Glatiramer Acetate 20 mg Per mL 16)

FDA Label Image

Glatiramer Acetate Injection 20 mg/ml (Box)

Label for Glatiramer Acetate Injection 20 mg/mL by Sun Pharmaceutical Industries, Inc. The label indicates it contains 30 single-dose pre-filled syringes for subcutaneous use and is for prescription use only.*

FDA Label Image

Figure 2 Glatiramer Acetate Injection (Glatiramer Acetate 20 mg Per mL 2)

A line graph comparing the cumulative number of enhancing lesions (median) over nine months between Glatiramer acetate injection and placebo. The x-axis represents months (0 to 9), and the y-axis represents the cumulative number of enhancing lesions. Two lines are plotted: a gray line for Glatiramer acetate injection and a black line for placebo, showing differences in lesion counts over time.*

FDA Label Image

Logo Sun Pharma (Glatiramer Acetate 20 mg Per mL 3)

FDA Label Image

Figure A (Glatiramer Acetate 20 mg Per mL 4)

An instructional diagram showing a sharps disposal container labeled with a biohazard symbol, a syringe in blister packaging, cotton balls, alcohol wipes, and an injection diary. The illustration is intended to represent items related to subcutaneous injection procedures, potentially for Glatiramer Acetate injection use.*

FDA Label Image

Figure B (Glatiramer Acetate 20 mg Per mL 5)

An instructional illustration showing two hands preparing an injection pen device, likely for subcutaneous administration. One hand holds the pen upright while the other hand removes or attaches the capped needle to the device.*

FDA Label Image

Figure C (Glatiramer Acetate 20 mg Per mL 6)

Illustrations showing recommended injection sites for Glatiramer Acetate solution, including the abdomen (avoiding 2 inches around the belly button), back of hips and arms (fleshy areas below the waist), arms (upper back portion), and thighs (about 2 inches above the knee and 2 inches below the groin).*

FDA Label Image

Figure D (Glatiramer Acetate 20 mg Per mL 7)

Illustration showing a person placing a small adhesive bandage on the lower abdomen, demonstrating post-injection care for a subcutaneous injection site.*

FDA Label Image

Figure E (Glatiramer Acetate 20 mg Per mL 8)

An instructional illustration showing a sequence of three steps for preparing a syringe injection. The images depict hands holding a syringe, removing a protective cap, and readying the syringe for use, likely to demonstrate proper injection preparation technique.*

FDA Label Image

Figure F (Glatiramer Acetate 20 mg Per mL 9)

Illustration showing a hand pinching a fold of skin, likely demonstrating proper technique for subcutaneous injection site preparation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.